69 related articles for article (PubMed ID: 1592101)
1. Myelofibrosis in primary myelodysplastic syndromes: a retrospective study of 352 patients.
Maschek H; Georgii A; Kaloutsi V; Werner M; Bandecar K; Kressel MG; Choritz H; Freund M; Hufnagl D
Eur J Haematol; 1992 Apr; 48(4):208-14. PubMed ID: 1592101
[TBL] [Abstract][Full Text] [Related]
2. The clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes.
Fu B; Ok CY; Goswami M; Xei W; Jaso JM; Muzzafar T; Bueso-Ramos C; Verstovsek S; Garcia-Manero G; Medeiros LJ; Wang SA
Ann Hematol; 2013 Oct; 92(10):1335-43. PubMed ID: 23660629
[TBL] [Abstract][Full Text] [Related]
3. Distinguishing myelodysplastic syndromes with moderate-to-severe bone marrow fibrosis from triple-negative primary myelofibrosis based on clinical and genetic covariates.
Wu J; Zhang W; Zhang P; Qin T; Xu Z; Sun Q; Jia Y; Qu S; Li B; Wang H; Pan L; Liu J; Zhang Y; Yan X; Gale RP; Xiao Z
Hematol Oncol; 2023 Aug; 41(3):598-602. PubMed ID: 36265165
[No Abstract] [Full Text] [Related]
4. Incidence of and risk factors for myelodysplastic syndrome in patients with rheumatologic diseases.
Kim YE; Ahn SM; Oh JS; Hong S; Lee CK; Yoo B; Kim YG
Rheumatology (Oxford); 2024 May; 63(5):1305-1312. PubMed ID: 37498607
[TBL] [Abstract][Full Text] [Related]
5. Defining disease modification in myelofibrosis in the era of targeted therapy.
Pemmaraju N; Verstovsek S; Mesa R; Gupta V; Garcia JS; Scandura JM; Oh ST; Passamonti F; Döhner K; Mead AJ
Cancer; 2022 Jul; 128(13):2420-2432. PubMed ID: 35499819
[TBL] [Abstract][Full Text] [Related]
6. Black African-American patients with primary myelofibrosis: a comparative analysis of phenotype and survival.
Gangat N; Kuykendall A; Al Ali N; Goel S; Abdelmagid M; Al-Kali A; Alkhateeb HB; Begna KH; Mangaonkar A; Litzow MR; Hogan W; Shah M; Patnaik MM; Pardanani A; Komrokji R; Tefferi A
Blood Adv; 2023 Jun; 7(12):2694-2698. PubMed ID: 36780345
[No Abstract] [Full Text] [Related]
7. Primary myelofibrosis evolving to an aplastic appearing marrow.
Schaefer JK; Choi SM; Luker GD; Chenevert TL; Ross BD; Talpaz M
Clin Case Rep; 2018 Jul; 6(7):1393-1395. PubMed ID: 29988611
[TBL] [Abstract][Full Text] [Related]
8. Maintaining MOMENTUM in myelofibrosis.
Kremyanskaya M; Marcellino BK
Lancet Haematol; 2023 Sep; 10(9):e697-e699. PubMed ID: 37517412
[No Abstract] [Full Text] [Related]
9. Quantitative analysis of bone marrow fibrosis highlights heterogeneity in myelofibrosis and augments histological assessment: An Insight from a phase II clinical study of zinpentraxin alfa.
Ryou H; Sirinukunwattana K; Wood R; Aberdeen A; Rittscher J; Weinberg OK; Hasserjian R; Pozdnyakova O; Peale F; Higgins B; Lundberg P; Trunzer K; Harrison CN; Royston D
Hemasphere; 2024 Jun; 8(6):e105. PubMed ID: 38884042
[No Abstract] [Full Text] [Related]
10. A rare case of primary myelofibrosis with novel cytogenetic abnormality - deletion 4q25.
Chattopadhyay D; Hajra S; Chandra H; Nath UK
Indian J Pathol Microbiol; 2024 Mar; ():. PubMed ID: 38563691
[No Abstract] [Full Text] [Related]
11. [How I treat primary myelofibrosis].
Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2019 Mar; 40(3):179-181. PubMed ID: 30929381
[No Abstract] [Full Text] [Related]
12. Myelodysplastic syndrome with myelofibrosis: myelodysplastic syndrome as a major primary disorder for acute myelofibrosis.
Takahashi M; Koike T; Nagayama R; Fujiwara M; Koyama S; Ohnishi M; Nakamori Y; Soga N; Aoki S; Tatewaki W
Clin Lab Haematol; 1991; 13(1):17-23. PubMed ID: 2060260
[TBL] [Abstract][Full Text] [Related]
13. Decoding Bone Marrow Fibrosis in Myelodysplastic Syndromes.
Melody M; Al Ali N; Zhang L; Ramadan H; Padron E; Sallman D; Sweet K; Lancet J; List A; Bennett JM; Komrokji R
Clin Lymphoma Myeloma Leuk; 2020 May; 20(5):324-328. PubMed ID: 32044274
[TBL] [Abstract][Full Text] [Related]
14. Bone marrow fibrosis in myelodysplastic syndromes: a prospective evaluation including mutational analysis.
Ramos F; Robledo C; Izquierdo-García FM; Suárez-Vilela D; Benito R; Fuertes M; Insunza A; Barragán E; Del Rey M; García-Ruiz de Morales JM; Tormo M; Salido E; Zamora L; Pedro C; Sánchez-Del-Real J; Díez-Campelo M; Del Cañizo C; Sanz GF; Hernández-Rivas JM;
Oncotarget; 2016 May; 7(21):30492-503. PubMed ID: 27127180
[TBL] [Abstract][Full Text] [Related]
15. Significance of bone marrow fibrosis in acute myeloid leukemia for survival in the real-world.
Zhang X; Wang F; Yu J; Jiang Z
Front Oncol; 2022; 12():971082. PubMed ID: 36276150
[TBL] [Abstract][Full Text] [Related]
16. Bone Marrow Fibrosis at Diagnosis and during the Course of Disease Is Associated with TP53 Mutations and Adverse Prognosis in Primary Myelodysplastic Syndrome.
Zhao Y; Guo J; Zhao S; Wang R; Shi L; Fang Y; Zhang Z; Song L; Wu D; Chang C
Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740649
[TBL] [Abstract][Full Text] [Related]
17. Myelodysplastic Syndromes with Bone Marrow Fibrosis: An Update.
Jain AG; Zhang L; Bennett JM; Komrokji R
Ann Lab Med; 2022 May; 42(3):299-305. PubMed ID: 34907099
[TBL] [Abstract][Full Text] [Related]
18. [Fibrosis-driving cells in patients with primary myelofibrosis and myelodysplastic syndromes with myelofibrosis].
Cai YN; Zhang PH; Fang LH; Liu JQ; Li B; Xu ZF; Qin TJ; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2020 Dec; 41(12):1002-1007. PubMed ID: 33445847
[No Abstract] [Full Text] [Related]
19. Guidelines on myelodysplastic syndromes: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular.
Magalhães SMM; Niero-Melo L; Chauffaille MLLF; Velloso EDRP; Lorand-Metze I; Buzzini R; Bernardo WM
Hematol Transfus Cell Ther; 2018; 40(3):255-261. PubMed ID: 30128435
[No Abstract] [Full Text] [Related]
20. Bone marrow fibrosis in chronic myelomonocytic leukemia is associated with increased megakaryopoiesis, splenomegaly and with a shorter median time to disease progression.
Petrova-Drus K; Chiu A; Margolskee E; Barouk-Fox S; Geyer J; Dogan A; Orazi A
Oncotarget; 2017 Nov; 8(61):103274-103282. PubMed ID: 29262560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
